BASF Coatings / Surventis: A Public-Information Transaction Reconstruction

This is an independent, public-source reconstruction of Carlyle and Qatar Investment Authority's acquisition of BASF's automotive OEM coatings, automotive refinish, and surface-treatment businesses. EOJI was not retained by any transaction party and had no access to confidential diligence, a quality-of-earnings report, a credit agreement, or a closing funds-flow statement.

EOJI analytical conclusion — not a transaction fact. Plausible only under substantial earnings normalization. The technical and commercial platform appears credible, but the transaction is not supported by FY2025 actual earnings on a conventional buyout basis.

Executive View

The transaction closed on 30 June 2026 at a reported €7.7 billion enterprise value. BASF reported approximately €5.8 billion of pre-tax cash proceeds, retained 40% of the standalone business now called Surventis, and left Carlyle and QIA with 60% controlling ownership. Those headline terms are directly supported by BASF's closing announcement and BASF's 2026 half-year report.

The analytical boundary is equally important. The exact sponsor capitalization, closing cash, debt-like items, revolving credit facility, covenants, hedges, transaction expenses, working-capital adjustment, tax structure, management equity, and composition of lender pro forma EBITDA remain undisclosed. The sources-and-uses reconstruction below is therefore an analytical bridge, not the confidential funds flow.

Evidence Status

The page keeps source authority and calculation status visible. Repetition in the press does not promote a secondary report to a primary fact.

Transaction at a Glance

Post-closing ownership and reported economics. Surventis is the standalone business formerly known as BASF Coatings. BASF’s 40% retained equity stake, the €7.7bn transaction enterprise value, approximately €5.8bn of pre-tax cash proceeds received by BASF, and approximately €1.3bn initial fair value of the retained interest are Reported. The 60% combined sponsor ownership is Derived as the complement to BASF’s disclosed stake. The allocation between Carlyle-managed funds and QIA, along with governance, dilution, funding, distributions, and exit rights, is Undisclosed.

Disclosed Facts and Disclosure Boundary

The approved source review found a coherent public perimeter, but not a complete capitalization or QoE bridge.

Transaction Mechanics, Sources and Uses, and Seller Rollover

The approximately 13x disclosure in BASF's closing announcement applies to the €8.7 billion value of the whole former Coatings division, including the separately sold decorative-paints business. It does not automatically describe the €7.7 billion Carlyle/QIA perimeter. BASF disclosed the decorative-paints transaction at approximately €981 million in its official closing release.

The €19 million residual supports perimeter coherence; it does not prove the legal allocation.

Undisclosed: The approximately €2.399 billion sponsor/QIA figure is a balancing item, not a disclosed equity cheque. The €352 million cash amount is a lender-derived proxy, not a contractual minimum cash requirement.

Lens 1 — Operating and Technical Diligence

Surventis combines long-lived qualification, full-layer OEM systems, refinish workflows, surface-treatment capabilities, and a broad production and technical network. Surventis's launch disclosure cites approximately €3.9 billion of current rounded annual sales, around 10,700 employees, more than 42,000 customers in over 140 countries, and more than 30 production and development sites. Those scale indicators do not reveal customer or plant economics.

The public record also identifies recent investment. BASF commissioned a high-runner OEM coatings plant in Münster after two and a half years of construction, while Caojing resin capacity increased from 8,000 to 18,800 tonnes per year. The increase is 135%, but neither the Münster release nor the Caojing release discloses utilization, yield, customer commitments, or recurring EBITDA benefit.

Formal qualification and delivery mechanisms are visible. Surventis describes an eleventh consecutive Airbus SQIP accreditation and more than 1,500 aerospace approvals and conformances; BASF describes Xiaomi full-layer systems from e-coat through clearcoat. These sources support technical depth, not customer economics. See the Airbus SQIP release, aerospace profile, and Xiaomi release.

Operating conclusion: Credible technical depth and value-creation options, but not yet a validated operating plan. Public awards, capacity announcements, and digital capabilities cannot be converted into EBITDA without plant, contract, and cash-benefit evidence.

Lens 2 — Valuation and Sponsor Return Sensitivities

The transaction's apparent entry multiple changes radically with the earnings definition. The €544 million public-evidence anchor is Derived from primary BASF disclosures. The €712 million, €800 million, and €880 million cases come from secondary process or lender reporting and remain sensitivities.

EBITDA-definition ladder. €544 million is Derived from primary evidence; €712 million, €800 million, and €880 million are Secondary report values. The chart does not validate the €336 million uplift from €544 million to €880 million.

The €336 million gap between €544 million and €880 million is the central unresolved variable. The public evidence identifies possible mechanisms—plant ramp, capacity, mix, workflow integration, and standalone transformation—but validates none of the uplift numerically. The public-evidence decision EBITDA therefore remains €544 million.

Public comparable EV/revenue analysis is corroboration, not a point fair value. Peer mix, margins, geography, capital intensity, pensions, leases, and transaction-affected prices prevent a mechanical average.

Axalta and AkzoNobel remain visible in the model but are excluded from clean headline statistics because their market prices were transaction-affected. Sherwin-Williams is a premium reference because architectural and retail coatings materially influence its valuation.

These outputs are scenario sensitivities, not disclosed sponsor returns. Actual sponsor capitalization, interim distributions, management equity, tax structure, lender add-backs, and exit mechanics remain undisclosed. A one-turn change in the base exit multiple changes enterprise value by approximately €806.5 million.

Lens 3 — Debt Capacity, Interest Coverage, Liquidity and Downside

The public financing reconstruction combines secondary lender-market reporting, official note-admission notices, and an official Bank of China release. It identifies approximately €4.508 billion of term loans and secured notes, but not an RCF or complete credit agreement.

The opening annual cash-interest proxy is approximately €283 million before hedging, fees, amortization, or RCF drawings. A 100 basis-point shock on approximately €2.62 billion of identified floating-rate debt adds approximately €26.2 million of annual interest.

Credit sensitivity. All three columns are Assumption/model outputs using the reported or secondary EBITDA definitions and the Derived financing reconstruction; they are not covenant calculations.

Credit conclusion: Debt capacity is conditional. The public model can quantify an approximately €349 million downside liquidity need, but cannot confirm that committed RCF capacity, covenant headroom, hedges, or tax structure are sufficient.

Lens 4 — Strategic and Execution Risks

The strategic thesis is plausible but weakly verified. Public evidence supports technical capabilities and execution mechanisms; the economics, concentration, and separation terms required for a high-confidence investment case remain private or undisclosed.

The European Commission's polysulfides remedy release supports a specific aerospace-sealant supply-chain risk: only two global suppliers, no available substitute, and costly, time-consuming switching and qualification. It does not support a claim that every Surventis product has the same exposure.

What Would Falsify the Positive Thesis?

Carve-Out and Technical Execution Questions

The diligence questions below are retained because a generic finance model cannot answer them. They connect operating evidence to cash, margin, liquidity, and downside.

Assumptions and Methodology

The analysis uses a primary-public-source-first hierarchy. Reported transaction values and audited financials form the anchor. Public comparables, a reverse LBO, debt-capacity analysis, asset and operating evidence, and implied-expectation tests provide independent challenges. Outputs are not mechanically averaged. Missing information remains missing or becomes an explicit scenario assumption.

Additional visible assumptions are a five-year holding period, 1.0% transaction fees, 1.5% financing fees excluding OID, a €352 million minimum-cash proxy, a 4.0% all-in RMB cash rate, working-capital-day scenarios, and 1.0% annual mandatory TLB amortization. None is presented as a reported transaction term.

Source Register

Material claims are linked where they appear above. This register identifies the main public authorities and secondary financing reports used in the page; private support material and internal QA are excluded.

Independent-Analysis Disclaimer

This Field Note is independent public-information analysis. EOJI is not affiliated with BASF, Surventis, Carlyle, QIA, their lenders, or their advisers, and was not engaged by a transaction party. It does not represent Carlyle's confidential investment case, a lender credit agreement, a closing funds-flow statement, a fairness opinion, or investment-decision-ready underwriting.

It does not constitute investment, credit, legal, regulatory, tax, accounting, financing, brokerage, or risk-management advice. It is not an offer, securities recommendation, financing recommendation, rating action, lending decision, transaction recommendation, or statement of confidential transaction economics. Company names and trademarks belong to their respective owners. Information is subject to correction as new public evidence becomes available.